Out of the Lab: Operationalizing Cell and Gene Therapy

What happens when a foreign manufacturer gets put on an FDA import alert? Or when a single undocumented ingredient turns a harmless dietary supplement into an unapproved drug?

In this episode of Out of the Lab, host Nico sits down with Dan and Binh from Wynngate Consulting. Bringing decades of insider FDA experience from compliance enforcement to foreign facility inspections, they pull back the curtain on the operational realities of GXP manufacturing. We explore the massive regulatory shifts brought on by the Food Safety Modernization Act (FSMA) and why the FDA's Foreign Supplier Verification Program has changed the game for importers.

In this episode, we cover:
The Overlapping 50%: The surprising similarities and critical differences between dietary supplement GMPs (Part 111) and pharmaceutical GMPs (Part 211).

The "Checking the Box" Trap: How an inadequate response to an FDA 483 observation can escalate into an Import Alert and a 10-year remediation nightmare.

Intentional vs. Accidental Adulteration: From shared line cross-contamination to companies secretly lacing weight-loss supplements with active pharmaceuticals to dodge clinical trials.

The Old FDA Adage: Why you can never test quality into a product once underlying GMP violations exist.

Supply Chain Resilience: Why vetting your foreign CDMO's quality management system is the ultimate risk mitigation technique for drug sponsors.

Dan and Binh consult on GxP compliance at Wynngate Consulting.Connect with them:

Dan Simonsen, Vice President: https://www.linkedin.com/in/danjsimonsen/

Binh Nguyen, President: https://www.linkedin.com/in/binh-nguyen-a77046190/

Visit their website:https://www.wynngateconsulting.com/

What are the hidden operational mistakes early-stage drug developers make before ever selecting a CDMO?
In this episode of Out of the Lab, host Nicholas Crudele sits down with David Dismuke, Chief Technology Officer at Forge Biologics. Drawing on over 20 years of experience across both academic CDMOs, corporate CDMOs, and therapeutic developers, David breaks down why yield should not be your only metric, how host cell DNA and empty/full ratios impact clinical timelines, and why a low-CV potency assay is your ultimate insurance policy during tech transfer.
In this episode, we cover:
The Yield Trap: Why focusing solely on viral titer masks critical quality attributes (CQAs) that can derail regulatory filings.

Empty vs. Full Capsid Ratios: Managing host cell DNA trade-offs and understanding route of administration impacts.

Potency Assays as Comparability Anchors: How high-throughput, sound analytical methods allow you to innovate safely in GMP environments.

Two-Sided Tech Transfer: Why you should never "throw the process over the wall" and how to execute proper gap analyses with your CDMO.

Single-Use Equipment: Navigating downstream chromatography hurdles and eliminating multi-product contact risks.

Why do biomanufacturing execution systems fail despite multi-million dollar investments?
In this episode of Out of the Lab, host Nicholas Crudele sits down with biopharma automation and manufacturing execution system (MES) consultant Robert Perks to unpack the realities of digitizing biomanufacturing workflows. From early R&D data integration to navigating the FDA’s shift toward Computer Software Assurance (CSA), Robert shares what it actually takes to achieve release by exception.

Key Topics Covered:
Cross-Functional Ownership: Why MES implementations fail when controlled by a single department.

CSV to CSA Shift: Moving away from binders of paper to risk-based critical thinking.

Designing for the Operator: Eliminating duplicated data entry and friction on the cleanroom floor.

Bridging R&D and Manufacturing: Leveraging early KPI and CQA data to build standardized Master Batch Records (MBRs).

Release by Exception: What infrastructure is required to make automated batch release a reality.

Timestamps:
00:00:00 – Introduction & Operational Scope

00:01:14 – What is an MES & Who Needs a Seat at the Table?

00:03:12 – When Should Early Biotechs Engage with MES?

00:07:55 – Operator Optimization & Reducing Data Duplication

00:11:46 – The Regulatory Paradigm Shift: From CSV to CSA

00:18:48 – Integrating R&D Data into Scale-Up Master Batch Records

00:26:44 – The Holy Grail: Achieving Release by Exception

Has the pharmaceutical industry outsourced its way into a supply chain crisis?
In this episode of Out of the Lab, host Nicholas Crudele sits down with repeat guest Hedley Rees to uncover the systemic risks embedded in the modern pharmaceutical manufacturing model. For decades, the industry has relied on outsourcing to CDMOs and offshoring to lower costs, but this shift has resulted in a devastating loss of internal critical assets and manufacturing capability.
Drawing on powerful analogies—from Apple's tight grip on iPhone manufacturing to Boeing's multi-billion-dollar Dreamliner outsourcing disaster—Hedley explains why pharmaceutical companies must bring clinical and manufacturing expertise back in-house. We also explore the historical success of process-driven drugs like Penicillin, and how current patent laws prioritizing molecule claims over scalable processes are driving massive phase-three failure rates.
In this episode, we cover:
The Boeing Dreamliner Analogy: The hidden costs and massive delays caused by fragmented supply chains.

Why CDMOs now own the "critical assets" of drug development, and how that strips product owners of competitive advantage.

The case for process patents over compound claims to reduce late-stage clinical failures.

Why early-stage CMC (Chemistry, Manufacturing, and Controls) must be at the center of IP and commercialization strategies.

The urgent need to reintegrate physicians and engineers directly into the early stages of drug supply chain design.

What happens when the biopharmaceutical industry tries to force living, hyper-perishable cell therapies into a legacy supply chain built for shelf-stable small molecules?
The entire system breaks down.
In this episode of Out of the Lab, host Nico sits down with Hedley Rees, Managing Director of PharmaFlow and a 40-year biopharma supply chain veteran, to pull back the curtain on why advanced therapies are hitting an operational dead end. Hedley details the immense logistical dangers of circular, "vein-to-vein" CAR-T workflows, the vulnerabilities left unaddressed by major wholesale distributors, and why the current industry model is built entirely on a structural paradox.
We pull apart:
The Evolution of Tech Friction: Why modern manufacturing architectures were never truly re-engineered to survive deep cryogenic and cold chain realities.

The 99% Attrition Trap: How archaic patent laws incentivize companies to claim molecules before establishing repeatable, scalable manufacturing processes.

Post-Contractual Moral Hazard: The commercial reality check of what happens when private-equity-backed CDMOs hold all the leverage, leaving asset owners to face regulatory scrutiny alone.

Back to the Future: Leveraging the collaboration model of Penicillin to integrate clinicians and engineers directly back into early-stage drug development.

Timestamps & Chapters:
00:00 – Introduction: Discussing operational complexity in cell and gene therapy.

01:44 – Alka-Seltzer vs. Monoclonal Antibodies: The failure to re-engineer legacy logistics.

03:34 – CAR-T Realities: Demystifying the highly volatile, circular "vein-to-vein" supply chain.

07:07 – Handover Hazards: Real-time tracking, temperature excursions, and runway failures.

13:26 – The Penicillin Blueprint: Why the earliest breakthrough required process over molecule.

19:39 – Changing the Rules: Redesigning patent law to solve structural asset attrition.

29:46 – The CDMO Leverage Trap: Navigating post-contractual moral hazard on the floor.

46:15 – Shared Risk Alliances: The future of integrated manufacturing capability.